CoChat

Polyagonists in Type 2 Diabetes Management

Dissanayake, H. A., Somasundaram, N. P. · 2024 · Current Diabetes Reports

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

Purpose of the review This review summarizes the new developments in polyagonist pharmacotherapy for type 2 diabetes.Recent findings Several dual- and triple-agonists targeting different pathogenic pathways of type 2 diabetes have entered clinical trials and have led to significant improvements in glycaemia, body weight, fatty liver, and cardio-renal risk factors, with variable adverse event profiles but no new serious safety concerns. Combining agents with complementary and synergistic mechanisms of action have enhanced efficacy and safety. Targeting multiple pathogenic pathways simultaneously has led to enhanced benefits which potentially match those of bariatric surgery. Tirzepatide, cotadutide, BI456906, ritatrutide, and CagriSema have entered phase 3 clinical trials. Outcomes from published clinical studies are reviewed. Efficacy-safety profiles are heterogeneous between agents, suggesting the potential application of precision medicine and need for personalized approach in pharmacological management of type 2 diabetes and obesity. Polyagonism has become a key strategy to address the complex pathogenesis of type 2 diabetes and co-morbidities and increasing number of agents are moving through clinical trials. Heterogeneity in efficacy-safety profiles calls for application of precision medicine and need for judicious personalization of care.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11892-023-01530-2

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 82 references

Research works printed but not linked: 2

  1. IDF Diabetes Atlas, 10th Edition [Internet]. Brussels, Belgium: Internation Diabetes Federation; 2021 [cited 2023 Sep 22]. Available from: https://www.diabetesatlas.org
  2. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021;398:143–55. Phase 3 randomized controlled clinical trial on tirzepatide in the treatment of type 2 diabetes. · DOI · Paper page

Cited by

See all 8

Metadata

Authors
Dissanayake, H. A., & Somasundaram, N. P.
Affiliations
University of Colombo (LK)
Corresponding author
Somasundaram, N. P.
Venue
Current Diabetes Reports
Published
2023-12-27
Volume
24
Issue
1
Pages
1-12
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
OpenAlex
W4390270426
Cited by
8
References
81
Citations by year
2025: 5 · 2024: 3
FWCI
0.29
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Diabetes Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes, dual agonist, tirzepatide, cotadutide, obesity, glycemic control, non-alcoholic fatty liver disease, precision medicine, pharmacotherapy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Body Weight, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Kidney, Risk Factors, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polyagonists in Type 2 Diabetes Management. https://app.cochat.ai/papers/10.1007/s11892-023-01530-2
The paper
Dissanayake, H. A., & Somasundaram, N. P. (2024). Polyagonists in Type 2 Diabetes Management. Current Diabetes Reports. https://doi.org/10.1007/s11892-023-01530-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.